share this article

Michael is a Director of Strategy in Pfizer’s World Wide R&D organization.  His group’s mission is to advance strategy and innovation in pharmaceutical development across all therapeutic areas.  His current focus is expanding the role of Artificial Intelligence in drug discovery to increase productivity and identify new therapies to help patients.

Prior to Pfizer, Michael was a Strategy Consultant at Strategy& (a PWC company) and PA Consulting.  He was also VP of technology at Phosplatin Therapeutics, a NYC biotech startup, and Director of BD and Commercial Operations at Forma Therapeutics (formerly CombinatoRx Singapore).

Michael has an MBA from Columbia Business School, and MS in Biomedical Engineering from Boston University, and a BA in Biology from University of Michigan.

share this article